IRVINE,
Calif., Nov. 1, 2022 /PRNewswire/ -- Edwards
Lifesciences (NYSE: EW) today announced that it has executed an
accelerated share repurchase agreement ("ASR") to
repurchase $750 million of Edwards' common stock.
With this transaction, Edwards has repurchased more than
$1.7 billion of shares in 2022.
Under the terms of this ASR, Edwards will receive an initial
delivery of approximately 8 million shares and the remainder at the
maturity of the ASR. The final number of shares to be
repurchased will be based on the volume weighted average share
price during the term of the agreement. The company is
funding the share repurchase under the ASR with its existing
cash.
Following this repurchase, Edwards has approximately $900
million remaining in its share repurchase authorization
approved by its Board of Directors.
About Edwards
Lifesciences
Edwards Lifesciences is the global leader of patient-focused
innovations for structural heart disease and critical care
monitoring. We are driven by a passion for patients,
dedicated to improving and enhancing lives through partnerships
with clinicians and stakeholders across the global healthcare
landscape. For more information, visit Edwards.com and follow us on
Facebook, Instagram, LinkedIn, Twitter and YouTube.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/edwards-lifesciences-announces-750-million-accelerated-share-repurchase-301664547.html
SOURCE Edwards Lifesciences Corporation